scholarly journals ANTIPLATELET AGENTS IN THE TREATMENT AND SECONDARY PREVENTION OF ISCHEMIC STROKE (REVIEW OF LITERATURE)

2017 ◽  
Vol 2 (2) ◽  
pp. 109-113
Author(s):  
Китаева ◽  
Elena Kitaeva ◽  
Шпрах ◽  
Vladimir Shprakh
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Antiplatelet Agents ◽  
Review Of Literature

scholarly journals Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention

Medicina ◽  
2021 ◽  
Vol 57 (1) ◽  
pp. 59
Author(s):  
Adam Wiśniewski
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Antiplatelet Therapy ◽  
Negative Impact ◽  
Platelet Reactivity ◽  
Antiplatelet Agent ◽  
Biological Response ◽  
Antiplatelet Agents ◽  
Platelet Inhibition ◽  
High Risk Group

Effective platelet inhibition is the main goal of the antiplatelet therapy recommended as a standard treatment in the secondary prevention of non-embolic ischemic stroke. Acetylsalicylic acid (aspirin) and clopidogrel are commonly used for this purpose worldwide. A low biological response to antiplatelet agents is a phenomenon that significantly reduces the therapeutic and protective properties of the therapy. The mechanisms leading to high on-treatment platelet reactivity are still unclear and remain multifactorial. The aim of the current review is to establish the background of resistance to antiplatelet agents commonly used in the secondary prevention of ischemic stroke and to explain the possible mechanisms. The most important factors influencing the incidence of a low biological response were demonstrated. The similarities and the differences in resistance to both drugs are emphasized, which may facilitate the selection of the appropriate antiplatelet agent in relation to specific clinical conditions and comorbidities. Despite the lack of indications for the routine assessment of platelet reactivity in stroke subjects, this should be performed in selected patients from the high-risk group. Increasing the detectability of low antiaggregant responders, in light of its negative impact on the prognosis and clinical outcomes, can contribute to a more individualized approach and modification of the antiplatelet therapy to maximize the therapeutic effect in the secondary prevention of stroke.

scholarly journals Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review

2021 ◽  
Vol 12 ◽  
Author(s):  
Martin Vališ ◽  
Blanka Klímová ◽  
Michal Novotný ◽  
Roman Herzig
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Antiplatelet Therapy ◽  
Antiplatelet Agent ◽  
Antiplatelet Agents ◽  
English Studies ◽  
Transient Ischemic Attacks ◽  
Severe Stroke ◽  
Neurological Outcomes ◽  
Ischemic Attack

The aim of this mini-review is to discuss the main antiplatelet agents that have been successfully used in the secondary prevention of non-cardioembolic ischemic stroke and transient ischemic attacks (TIA). The methodology is based on a literature review of available peer-reviewed English studies listed in PubMed. The findings reveal that aspirin remains a reliable antiplatelet agent in the secondary prevention of acute non-cardioembolic ischemic stroke and TIA. Nevertheless, currently, there are also other agents, i.e., ticagrelor, clopidogrel, and cilostazol, that can be applied. In addition, the results indicate that time is significant not only in severe stroke but also in non-severe stroke and TIA, which suggests that antiplatelet therapy should be applied within 24 h after the first symptoms because early treatment can lead to an improvement in neurological outcomes and reduce the chance of an early subsequent stroke.

ANTIPLATELET AGENTS IN THE TREATMENT AND SECONDARY PREVENTION OF PEDIATRIC ARTERIAL ISCHEMIC STROKE: THE STATE OF THE PROBLEM

2021 ◽  
Vol 100 (5) ◽  
pp. 151-159
Author(s):  
I.B. Komarova ◽  
Keyword(s):  
Ischemic Stroke ◽  
Clinical Practice ◽  
Secondary Prevention ◽  
Acetylsalicylic Acid ◽  
Antiplatelet Agents ◽  
First Year ◽  
Evidence Based ◽  
Arterial Ischemic Stroke ◽  
Level Of Evidence ◽  
Low Level

Arterial ischemic stroke (AIS) in children is a potentially disabling disease with cumulative rates of relapse in the first year of 12–16%, necessitating secondary prevention of the disease. Both in adults and in pediatric clinical practice, acetylsalicylic acid is most commonly used, much less often – clopidogrel. However, the validity of the use of antiplatelet agents in children with ischemic stroke is still controversial, due to the low level of evidence-based studies and the paucity of publications. The article analyzes and summarizes data on the possibilities and limitations of the use of antiplatelet agents for secondary prevention of AIS in children.

scholarly journals Antithrombotic Therapy for Secondary Prevention in Patients with Non-Cardioembolic Stroke or Transient Ischemic Attack: A Systematic Review

Life ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 447
Author(s):  
Dániel Tornyos ◽  
Alexandra Bálint ◽  
Péter Kupó ◽  
Oumaima El Alaoui El Abdallaoui ◽  
András Komócsi
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Randomized Controlled Trials ◽  
Transient Ischemic Attack ◽  
Antiplatelet Agents ◽  
Cochrane Library ◽  
Stroke Recurrence ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Ischemic Attack

Stroke embodies one of the leading causes of death and disability worldwide. We aimed to provide a comprehensive insight into the effectiveness and safety of antiplatelet agents and anticoagulants in the secondary prevention of ischemic stroke or transient ischemic attack. A systematic search for randomized controlled trials, comparing antiplatelet or anticoagulant therapy versus aspirin or placebo among patients with ischemic stroke or transient ischemic attack, was performed in order to summarize data regarding the different regimens. Keyword-based searches in the MEDLINE, EMBASE, and Cochrane Library databases were conducted until the 1st of January 2021. Our search explored 46 randomized controlled trials involving ten antiplatelet agents, six combinations with aspirin, and four anticoagulant therapies. The review of the literature reflects that antiplatelet therapy improves outcome in patients with ischemic stroke or transient ischemic attack. Monotherapy proved to be an effective and safe choice, especially in patients with a high risk of bleeding. Intensified antiplatelet regimens further improve stroke recurrence; however, bleeding rate increases while mortality remains unaffected. Supplementing the clinical judgment of stroke treatment, assessment of bleeding risk is warranted to identify patients with the highest benefit of treatment intensification.

Management of patients after ischemic stroke

2020 ◽  
Vol 25 (5) ◽  
pp. 51-57
Author(s):  
V. A. Parfenov
Keyword(s):  
Ischemic Stroke ◽  
Secondary Prevention ◽  
Antihypertensive Drugs ◽  
Oral Anticoagulants ◽  
Antiplatelet Agents ◽  
International Normalized Ratio ◽  
Excess Body Weight ◽  
Nonvalvular Atrial Fibrillation ◽  
Regular Intake

Rehabilitation and secondary prevention of ischemic stroke (IS) is the basis for the management of patients with ischemic stroke. The important role of non-drug methods of secondary prevention of IS should be noted: cessation of smoking and alcohol abuse, regular physical activity, proper nutrition, reduction of excess body weight. The normalization of blood pressure is one of the most effective areas of IS prevention. It is based on the regular intake of antihypertensive drugs in most cases. After noncardioembolic IS, antiplatelet agents are required: acetylsalicylic acid (ASA), clopidogrel, or a combination of dipyridamole and ASA. The possibility of taking a combination of clopidogrel and ASA for 21 days after IS with a subsequent switch to monotherapy with ASA or clopidogrel is discussed in patients with non-disabling IS. After cardiomoembolic IS, warfarin is required under the control of an international normalized ratio or with nonvalvular atrial fibrillation of new oral anticoagulants: apixaban, dabigatran or rivaroxaban. Most patients after IS require statins, and the doses are selected individually. Carotid endarterectomy is most effective in severe stenosis (narrowing of 70–99% of the diameter) of the internal carotid artery on the side of the involved hemisphere during the first 3–7 days after non-disabling IS. The data of multicenter placebo-controlled and open observational studies on the use of the metabolic drug Cytoflavin, which is widely used in our country in the rehabilitation of patients with IS, are presented.

Abstract P1: Antiplatelet Therapy for Secondary Prevention After Ischemic Stroke: Systematic Review and a Network Meta-Analysis From Randomized Trials

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Takahisa Mikami ◽  
Michika Sakamoto ◽  
Toshiki Kuno ◽  
Akira Machida ◽  
Evan Siau ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Combination Therapy ◽  
Secondary Prevention ◽  
Major Bleeding ◽  
Recurrent Stroke ◽  
Meta Analysis ◽  
Antiplatelet Agents ◽  
Similar Efficacy ◽  
Significant Heterogeneity ◽  
Significant Difference

Introduction: While various antiplatelet regimens are currently available for secondary prevention after ischemic stroke, data comparing their efficacy and safety are scarce. We conducted a network meta-analysis investigating the efficacy and risk profile of each antiplatelet regimen including combination therapies for secondary prevention of recurrent stroke. Methods: PubMed and EMBASE were searched for reports on randomized controlled trials published between January 1, 1985, and July 21, 2020. Random-effects model was used for meta-analysis. Primary outcome was recurrent stroke after ischemic stroke and secondary outcomes was major bleeding. Results: 39 trials enrolling a total of 158,507 patients were eligible for our network meta-analysis. Patients were randomly allocated to receive aspirin, cilostazol, clopidogrel, dipyridamole, ticagrelor, ticlopidine, or combination of these antiplatelet agents in each study. In comparison to those who received aspirin monotherapy, the risk of recurrent stroke was significantly lower in patients who received cilostazol (odds ratio (OR), 0.65; 95% confidence interval (CI), 0.51-0.83), aspirin + ticagrelor (OR, 0.72; 95% CI, 0.62-0.83), aspirin + clopidogrel (OR, 0.73; 95% CI, 0.54-0.98) without significant heterogeneity (I2=45.1). Ticagrelor monotherapy did not demonstrate a significant difference in risk of recurrent stroke compared to clopidogrel monotherapy (OR, 1.02; 95% CI, 0.70-1.48). Aspirin and ticagrelor combination therapy did not demonstrate a significant difference in risk of recurrent stroke compared to aspirin and clopidogrel combination therapy (OR, 1.01; 95% CI, 0.74-1.39). Combination therapy of aspirin with clopidogrel or ticagrelor showed a higher risk of major bleeding compared to aspirin monotherapy (OR, 1.54; 95% CI, 1.30-1.84; OR, 2.93; 95% CI, 1.53-5.41, respectively). Conclusions: Ticagrelor and clopidogrel demonstrated similar efficacy and risk of major bleeding—as monotherapy and in combination with aspirin—when used for secondary prevention of recurrent stroke. Ticagrelor or clopidogrel in combination with aspirin showed lower risk of recurrent stroke but higher risk of major bleeding than aspirin monotherapy.

Sign in / Sign up

Export Citation Format

Share Document